Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy.

ABSTRACT:

Background

Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression.

Methods

Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ≥100

SUBMITTER: Singini I 

PROVIDER: S-EPMC5276794 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature